New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
Trinity Biotech announced results from a pre-pivotal clinical trial showing its CGM+ platform can successfully distinguish between true blood glucose lows and false lows caused by nocturnal sensor compression. The analysis of over 5,000 hours of wear data validates the multi-sensor architecture's ability to provide physiological context, addressing a common limitation in the $15 billion global CGM market.
Key figures
- Cgm market size
- $15 billion
- Wear data hours
- 5,000
- Compression low frequency
- once every 5 to 6 days
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.